<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00364819</url>
  </required_header>
  <id_info>
    <org_study_id>200614025</org_study_id>
    <nct_id>NCT00364819</nct_id>
  </id_info>
  <brief_title>Initial Study of Rituximab to Treat Primary Biliary Cirrhosis</brief_title>
  <official_title>Effects of Rituximab (Rituxan) on B Cell and AMA Response in Patients With Primary Biliary Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety of the anti-CD20 antibody rituximab in
      treating patients with Primary Biliary Cirrhosis (PBC). Rituximab is a laboratory-made
      antibody currently used to treat some kinds of lymphoma. Rituximab may also help people with
      PBC, a disease of the immune system. However, the safety of rituximab in PBC patients must
      first be established.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot, open-label, study on 10 female patients with AMA-positive PBC to determine
      the effects of two infusions of rituximab on response of memory B cells to bacterial motifs,
      on biochemical function, and histological features. We will enroll 10 consecutive
      AMA-positive patients with the diagnosis of PBC based on internationally accepted criteria
      and histological staging determined at liver biopsy and being currently treated with UDCA.
      Importantly, patients with advanced histological stages, decompensated liver disease, or
      waiting for OLT will not be included in the study (see exclusion criteria).

      Patients eligible and willing to enter the study will be evaluated at baseline by isolation
      and study of frequency and absolute numbers of B cells and their function, biochemical and
      AMA tests. Histology and quality of life will be also evaluated in all patients. The
      methodology to be used for B cell study is already well-established in our laboratory as can
      be seen in the attached paper (Kikuchi et al. 2005b). Patients will be administered 1,000 mg
      rituximab intravenously by slow infusion on Day 1 and Day 15 (+/- 1 day). Rituximab's
      pharmacokinetics indicate that complete B cell depletion is obtained 2-3 days after
      administration and that such effect may be lost after 9 months (Vieira et al. 2004). In
      addition to our B cell work, serum samples will undergo AMA testing, including titers, using
      recombinant mitochondrial antigens (Miyakawa et al. 2001). Patients will also undergo serum
      chemistry panel, which includes liver function tests. Patients will continue on a steady dose
      of UDCA therapy throughout the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Immunoglobulin G</measure>
    <time_frame>52 Weeks</time_frame>
    <description>The difference in serum immunoglobulin G from Baseline to Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Immunoglobulin A</measure>
    <time_frame>52 Weeks</time_frame>
    <description>The difference in serum immunoglobulin A from Baseline to Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Immunoglobulin M</measure>
    <time_frame>52 Weeks</time_frame>
    <description>The difference in serum immunoglobulin M from Baseline to Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Alkaline Phosphatase</measure>
    <time_frame>52 Weeks</time_frame>
    <description>The difference in serum alkaline phosphatase from Baseline to Week 52</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Primary Biliary Cirrhosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rituximab 1000 mg IV on days 1 and 15, given over 5 - 6 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>rituximab 1000 mg IV day 1 and 15, given over 5 - 6 hours</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Rituxan (R)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Liver biopsy showing histological PBC stages I, II, or III

          -  Presence of all criteria for the diagnosis of PBC

          -  serum AMA at titer &gt;1:40

          -  alkaline phosphatase &gt;2X normal value for &gt;6 months

          -  compatible liver histology

          -  Incomplete response to UDCA after 6 months of treatment.

          -  Negative pregnancy test (female patients in fertile age)

          -  Adequate renal function (serum creatinine &lt; 1.2)

        Exclusion Criteria:

          -  End-stage/decompensated liver disease

          -  ascites

          -  jaundice with serum bilirubin &gt; 2mg/dl

          -  history of digestive bleeding secondary to portal hypertension or endoscopic evidence
             of varices at stage F2

          -  history of hepatic encephalopathy

          -  INR&gt;1.2

          -  Other coexisting causes of liver disease

          -  Use of other immunosuppressive medications 4 weeks prior to enrollment

          -  Diuretics use
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M. Eric Gershwin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christopher L Bowlus, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.liverfoundation.org</url>
    <description>American Liver Foundation</description>
  </link>
  <link>
    <url>http://www.pbcers.org</url>
    <description>Primary Biliary Cirrhosis Organization</description>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2006</study_first_submitted>
  <study_first_submitted_qc>August 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2006</study_first_posted>
  <results_first_submitted>March 18, 2017</results_first_submitted>
  <results_first_submitted_qc>May 1, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 1, 2017</results_first_posted>
  <last_update_submitted>June 5, 2017</last_update_submitted>
  <last_update_submitted_qc>June 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Davis</investigator_affiliation>
    <investigator_full_name>Merrill Eric Gershwin, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Primary Biliary Cirrhosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD may be shared upon request and appropriate approval from Institutional Review Boards and material transfer agreements. No patient identifiers will be shared. Requests for IPD may be made to the Principle Investigator.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Open Label Study Arm</title>
          <description>Primary Biliary Cirrhosis
rituximab: rituximab 1000 mg IV day 1 and 15, given over 5 - 6 hours</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Open Label Study Arm</title>
          <description>Primary Biliary Cirrhosis
rituximab: rituximab 1000 mg IV day 1 and 15, given over 5 - 6 hours</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Anti-mitochondrial Antibody</title>
          <description>Serum anti-mitochondrial antibodies (AMA) are present in 90% of cases of PBC.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Anti-mitochondrial Antibody Positive</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Anti-mitochondrial Antibody Negative</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Liver Biopsy Stage</title>
          <description>Staging of liver histology by Ludwig from earliest stage (I) to latest stage (IV). Stage I: Portal inflammation, bile duct abnormalities, or both are present; Stage II: Periportal fibrosis is present, with or without periportal inflammation or prominent enlargement of the portal tracts with seemingly intact, newly formed limiting plates; Stage III: Septal fibrosis with active inflammatory, passive paucicellular septa, or both are present; Stage IV: Nodules with various degrees of inflammation are present</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Ludwig Stage I</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Ludwig Stage II</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Ludwig Stage III</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Ludwig Stage IV</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events</title>
        <time_frame>52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Open Label Study Arm</title>
            <description>Primary Biliary Cirrhosis
rituximab: rituximab 1000 mg IV day 1 and 15, given over 5 - 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Serious Adverse Events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-Serious Adverse Events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Immunoglobulin G</title>
        <description>The difference in serum immunoglobulin G from Baseline to Week 52</description>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Open Label Study Arm</title>
            <description>Primary Biliary Cirrhosis
rituximab: rituximab 1000 mg IV day 1 and 15, given over 5 - 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Immunoglobulin G</title>
          <description>The difference in serum immunoglobulin G from Baseline to Week 52</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167" spread="450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Immunoglobulin A</title>
        <description>The difference in serum immunoglobulin A from Baseline to Week 52</description>
        <time_frame>52 Weeks</time_frame>
        <population>1 subject with missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Study Arm</title>
            <description>Primary Biliary Cirrhosis
rituximab: rituximab 1000 mg IV day 1 and 15, given over 5 - 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Immunoglobulin A</title>
          <description>The difference in serum immunoglobulin A from Baseline to Week 52</description>
          <population>1 subject with missing data.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.8" spread="89.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Immunoglobulin M</title>
        <description>The difference in serum immunoglobulin M from Baseline to Week 52</description>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Open Label Study Arm</title>
            <description>Primary Biliary Cirrhosis
rituximab: rituximab 1000 mg IV day 1 and 15, given over 5 - 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Immunoglobulin M</title>
          <description>The difference in serum immunoglobulin M from Baseline to Week 52</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121" spread="74.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Alkaline Phosphatase</title>
        <description>The difference in serum alkaline phosphatase from Baseline to Week 52</description>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Open Label Study Arm</title>
            <description>Primary Biliary Cirrhosis
rituximab: rituximab 1000 mg IV day 1 and 15, given over 5 - 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Alkaline Phosphatase</title>
          <description>The difference in serum alkaline phosphatase from Baseline to Week 52</description>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.8" spread="151.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>52 weeks after initial infusion of rituximab</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Open Label Study Arm</title>
          <description>Primary Biliary Cirrhosis
rituximab: rituximab 1000 mg IV day 1 and 15, given over 5 - 6 hours</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Shingles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hyperpigmentation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christopher L. Bowlus, MD</name_or_title>
      <organization>University of California Davis</organization>
      <phone>916-734-8986</phone>
      <email>clbowlus@ucdavis.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

